275 related articles for article (PubMed ID: 22583931)
41. Salinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesis.
Li T; Liu X; Shen Q; Yang W; Huo Z; Liu Q; Jiao H; Chen J
Oncotarget; 2016 May; 7(18):26580-92. PubMed ID: 27058891
[TBL] [Abstract][Full Text] [Related]
42. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
43. OSU-A9 inhibits angiogenesis in human umbilical vein endothelial cells via disrupting Akt-NF-κB and MAPK signaling pathways.
Omar HA; Arafa el-SA; Salama SA; Arab HH; Wu CH; Weng JR
Toxicol Appl Pharmacol; 2013 Nov; 272(3):616-24. PubMed ID: 23921148
[TBL] [Abstract][Full Text] [Related]
44. Orally Administered Mucolytic Drug l-Carbocisteine Inhibits Angiogenesis and Tumor Growth in Mice.
Shinya T; Yokota T; Nakayama S; Oki S; Mutoh J; Takahashi S; Sato K
J Pharmacol Exp Ther; 2015 Sep; 354(3):269-78. PubMed ID: 26126534
[TBL] [Abstract][Full Text] [Related]
45. Novel PI3K/AKT targeting anti-angiogenic activities of 4-vinylphenol, a new therapeutic potential of a well-known styrene metabolite.
Yue GG; Lee JK; Kwok HF; Cheng L; Wong EC; Jiang L; Yu H; Leung HW; Wong YL; Leung PC; Fung KP; Lau CB
Sci Rep; 2015 Jun; 5():11149. PubMed ID: 26053458
[TBL] [Abstract][Full Text] [Related]
46. Tanshinone IIA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1α in hypoxic microenvironments in human colorectal cancer.
Sui H; Zhao J; Zhou L; Wen H; Deng W; Li C; Ji Q; Liu X; Feng Y; Chai N; Zhang Q; Cai J; Li Q
Cancer Lett; 2017 Sep; 403():86-97. PubMed ID: 28602978
[TBL] [Abstract][Full Text] [Related]
47. Platycodin D inhibits tumor growth by antiangiogenic activity via blocking VEGFR2-mediated signaling pathway.
Luan X; Gao YG; Guan YY; Xu JR; Lu Q; Zhao M; Liu YR; Liu HJ; Fang C; Chen HZ
Toxicol Appl Pharmacol; 2014 Nov; 281(1):118-24. PubMed ID: 25250884
[TBL] [Abstract][Full Text] [Related]
48. Cat's whiskers tea (Orthosiphon stamineus) extract inhibits growth of colon tumor in nude mice and angiogenesis in endothelial cells via suppressing VEGFR phosphorylation.
Ahamed MB; Aisha AF; Nassar ZD; Siddiqui JM; Ismail Z; Omari SM; Parish CR; Majid AM
Nutr Cancer; 2012; 64(1):89-99. PubMed ID: 22136553
[TBL] [Abstract][Full Text] [Related]
49. DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Oncotarget; 2016 Sep; 7(39):63124-63137. PubMed ID: 27517319
[TBL] [Abstract][Full Text] [Related]
50. SKLB-M8 induces apoptosis through the AKT/mTOR signaling pathway in melanoma models and inhibits angiogenesis with decrease of ERK1/2 phosphorylation.
Wang J; Yang Z; Wen J; Ma F; Wang F; Yu K; Tang M; Wu W; Dong Y; Cheng X; Nie C; Chen L
J Pharmacol Sci; 2014; 126(3):198-207. PubMed ID: 25341684
[TBL] [Abstract][Full Text] [Related]
51. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
52. The extract of Polygoni Cuspidati Rhizoma et Radix suppresses the vascular endothelial growth factor-induced angiogenesis.
Hu WH; Chan GK; Lou JS; Wu QY; Wang HY; Duan R; Cheng MY; Dong TT; Tsim KW
Phytomedicine; 2018 Mar; 42():135-143. PubMed ID: 29655679
[TBL] [Abstract][Full Text] [Related]
53. ZLM-7 exhibits anti-angiogenic effects via impaired endothelial cell function and blockade of VEGF/VEGFR-2 signaling.
Su M; Huang J; Li J; Qin X; Tang X; Jin F; Chen S; Jiang C; Zou Z; Peng K; Nuruzzaman M; Zhang J; Luo J; Liu S; Luo Z
Oncotarget; 2016 Apr; 7(14):19018-30. PubMed ID: 26967559
[TBL] [Abstract][Full Text] [Related]
54. NSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesis.
Yu P; Ye L; Wang H; Du G; Zhang J; Zuo Y; Zhang J; Tian J
PLoS One; 2014; 9(12):e115041. PubMed ID: 25551444
[TBL] [Abstract][Full Text] [Related]
55. DSGOST inhibits tumor growth by blocking VEGF/VEGFR2-activated angiogenesis.
Choi HS; Lee K; Kim MK; Lee KM; Shin YC; Cho SG; Ko SG
Oncotarget; 2016 Apr; 7(16):21775-85. PubMed ID: 26967562
[TBL] [Abstract][Full Text] [Related]
56. DCT015, a new sorafenib derivate, inhibits tumor growth and angiogenesis in gastric cancer models.
Wang W; Wang H; Ni Y; Yao Z; Ye L; Tian J
Tumour Biol; 2016 Jul; 37(7):9221-32. PubMed ID: 26768619
[TBL] [Abstract][Full Text] [Related]
57. Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma.
Torimura T; Iwamoto H; Nakamura T; Abe M; Ikezono Y; Wada F; Sakaue T; Masuda H; Hashimoto O; Koga H; Ueno T; Yano H
Neoplasia; 2016 Jul; 18(7):413-24. PubMed ID: 27435924
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of Endothelial SCUBE2 (Signal Peptide-CUB-EGF Domain-Containing Protein 2), a Novel VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) Coreceptor, Suppresses Tumor Angiogenesis.
Lin YC; Liu CY; Kannagi R; Yang RB
Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1202-1215. PubMed ID: 29545238
[TBL] [Abstract][Full Text] [Related]
59. Celastrus orbiculatus extract inhibits tumor angiogenesis by targeting vascular endothelial growth factor signaling pathway and shows potent antitumor activity in hepatocarcinomas in Vitro and in Vivo.
Qian YY; Zhang H; Hou Y; Yuan L; Li GQ; Guo SY; Hisamits T; Liu YQ
Chin J Integr Med; 2012 Oct; 18(10):752-60. PubMed ID: 21805294
[TBL] [Abstract][Full Text] [Related]
60. A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities.
Awazu Y; Nakamura K; Mizutani A; Kakoi Y; Iwata H; Yamasaki S; Miyamoto N; Imamura S; Miki H; Hori A
Mol Cancer Ther; 2013 Jun; 12(6):913-24. PubMed ID: 23548264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
